NURECA.NS
Nureca Limited [NURECA.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NURECA.NS Stock Summary
Top 10 Correlated Stocks
NURECA.NS
In the News
NURECA.NS Financial details
Company Rating
Buy
Market Cap
2.9B
Income
8.22M
Revenue
961.84M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
102
Optionable
No
Shortable
Yes
Earnings
31 Dec 2022
P/E
433.7
Forward P/E
-
PEG
-44.18
P/S
4.1
P/B
2.11
P/C
-
P/FCF
-
Quick Ratio
15.03
Current Ratio
20.9
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.82
EPS next Y
-
EPS next Q
-
EPS this Y
-118.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
12.46%
Revenue Q/Q
-28.64%
EPS Q/Q
-94.12%
-
-
-
-
SMA20
-7.47%
SMA50
-22.97%
SMA100
-20.61%
Inst Own
-
Inst Trans
-
ROA
-
ROE
1%
ROC
-
Gross Margin
36%
Oper. Margin
-1%
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
253.5-468.8
52W High
-40.97%
52W Low
+9.19%
RSI
39
Rel Volume
0.49
Avg Volume
32.53K
Volume
15.81K
Perf Week
-4.81%
Perf Month
-19.38%
Perf Quarter
-16.92%
Perf Half Y
-22.66%
-
-
-
-
Beta
0.165
-
-
Volatility
6.32%, 18.57%
Prev Close
-0.02%
Price
276.25
Change
-3.04%
NURECA.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 88.38 | 99.43K | 285.54 | 255.54 | 111.32 | |
| Net income per share | 8.89 | 6.4K | 62.04 | 44.96 | -8.25 | |
| Operating cash flow per share | 0.44 | -7.92K | 46.64 | 1.4 | 10.23 | |
| Free cash flow per share | 0.27 | -8.34K | 45.67 | -4.6 | 9.83 | |
| Cash per share | 0.16 | 74 | 169.48 | 100.05 | 134.15 | |
| Book value per share | 12.2 | 14.93K | 218.18 | 203.19 | 194.88 | |
| Tangible book value per share | 12.2 | 14.93K | 217.78 | 200.38 | 192.27 | |
| Share holders equity per share | 12.2 | 14.93K | 218.18 | 203.19 | 194.88 | |
| Interest debt per share | 0.77 | 10.2K | 7.17 | 4.84 | 3.78 | |
| Market cap | 4.52B | 6.46M | 4.49B | 13.68B | 3B | |
| Enterprise value | 4.53B | 103.51M | 4.36B | 13.64B | 3.02B | |
| P/E ratio | 72.64 | 0.1 | 9.69 | 30.43 | -36.31 | |
| Price to sales ratio | 7.31 | 0.01 | 2.1 | 5.35 | 2.69 | |
| POCF ratio | 1.48K | -0.08 | 12.89 | 977.97 | 29.29 | |
| PFCF ratio | 2.42K | -0.08 | 13.16 | -297.43 | 30.47 | |
| P/B Ratio | 52.92 | 0.04 | 2.75 | 6.73 | 1.54 | |
| PTB ratio | 52.92 | 0.04 | 2.75 | 6.73 | 1.54 | |
| EV to sales | 7.31 | 0.1 | 2.04 | 5.34 | 2.72 | |
| Enterprise value over EBITDA | 50.23 | 1.1 | 6.67 | 21.65 | -38.26 | |
| EV to operating cash flow | 1.48K | -1.31 | 12.5 | 975.22 | 29.57 | |
| EV to free cash flow | 2.42K | -1.24 | 12.77 | -296.59 | 30.76 | |
| Earnings yield | 0.01 | 9.9 | 0.1 | 0.03 | -0.03 | |
| Free cash flow yield | 0 | -12.91 | 0.08 | 0 | 0.03 | |
| Debt to equity | 0.05 | 0.65 | 0.02 | 0.02 | 0.02 | |
| Debt to assets | 0.02 | 0.29 | 0.02 | 0.02 | 0.02 | |
| Net debt to EBITDA | 0.04 | 1.03 | -0.2 | -0.06 | -0.36 | |
| Current ratio | 1.56 | 3.45 | 9.6 | 16.85 | 21 | |
| Interest coverage | 80.34 | 22.03 | 41.36 | 123.92 | -38.65 | |
| Income quality | 0.03 | -0.92 | 0.56 | 0.02 | -0.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0.11 | 0 | |
| Sales general and administrative to revenue | 0 | 0.01 | 0 | 0.02 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.01 | 0.01 | |
| Capex to operating cash flow | -0.39 | 0.05 | -0.02 | -4.29 | -0.04 | |
| Capex to revenue | 0 | 0 | 0 | -0.02 | 0 | |
| Capex to depreciation | -2.13 | -1.1 | -1.72 | -4.05 | -0.17 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 49.4 | 46.36K | 551.85 | 453.37 | 190.19 | |
| ROIC | 0.67 | 0.27 | 0.27 | 0.19 | -0.07 | |
| Return on tangible assets | 0.26 | 0.19 | 0.25 | 0.21 | -0.04 | |
| Graham Net | -2.07 | 1.52K | 181.3 | 147.39 | 143.61 | |
| Working capital | 82.72M | 232.49M | 1.62B | 1.94B | 1.78B | |
| Tangible asset value | 85.47M | 149.59M | 1.63B | 2B | 1.92B | |
| Net current asset value | 79.85M | 138.03M | 1.58B | 1.9B | 1.75B | |
| Invested capital | 0.05 | 0.65 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 44.28M | 125.52M | 168.57M | 298.61M | 237.41M | |
| Average payables | 75.13M | 77.96M | 72.88M | 67.33M | 48.56M | |
| Average inventory | 85.44M | 149.88M | 266.01M | 499.77M | 488.27M | |
| Days sales outstanding | 52.22 | 59.64 | 29.87 | 60.35 | 17.14 | |
| Days payables outstanding | 88.72 | 32.94 | 32.08 | 12.99 | 24.11 | |
| Days of inventory on hand | 123.16 | 92.81 | 134.93 | 173.87 | 166.61 | |
| Receivables turnover | 6.99 | 6.12 | 12.22 | 6.05 | 21.3 | |
| Payables turnover | 4.11 | 11.08 | 11.38 | 28.09 | 15.14 | |
| Inventory turnover | 2.96 | 3.93 | 2.71 | 2.1 | 2.19 | |
| ROE | 0.73 | 0.43 | 0.28 | 0.22 | -0.04 | |
| Capex per share | -0.17 | -412 | -0.97 | -6 | -0.4 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 27.79 | 21.23 | 21.23 | 31.35 | 22.37 | |
| Net income per share | 0.3 | -1.53 | -0.71 | 2.89 | 0.16 | |
| Operating cash flow per share | 1.2 | 1.12 | 1.17 | 1.18 | 1.18 | |
| Free cash flow per share | 1.2 | 1.12 | 1.17 | 1.18 | 1.18 | |
| Cash per share | 127.92 | 134.15 | 102.06 | 134.75 | 0 | |
| Book value per share | 196.24 | 194.88 | 194.88 | 197.04 | 0 | |
| Tangible book value per share | 0 | 192.27 | 0 | 194.58 | 0 | |
| Share holders equity per share | 196.24 | 194.88 | 194.88 | 197.04 | 0 | |
| Interest debt per share | 0.11 | 3.43 | 0.12 | 2.84 | 0.11 | |
| Market cap | 4.98B | 3B | 3.67B | 3.36B | 4.23B | |
| Enterprise value | 6.26B | 3.02B | 4.7B | 3.37B | 4.23B | |
| P/E ratio | 413.75 | -48.95 | -129.94 | 29.03 | 640.24 | |
| Price to sales ratio | 17.93 | 14.11 | 17.31 | 10.72 | 18.89 | |
| POCF ratio | 414.44 | 266.98 | 315.14 | 285.76 | 357.49 | |
| PFCF ratio | 414.44 | 266.98 | 315.14 | 285.76 | 357.49 | |
| P/B Ratio | 2.54 | 1.54 | 1.89 | 1.71 | 0 | |
| PTB ratio | 2.54 | 1.54 | 1.89 | 1.71 | 0 | |
| EV to sales | 22.53 | 14.25 | 22.11 | 10.76 | 18.89 | |
| Enterprise value over EBITDA | 638.86 | -231.18 | -2.04K | 73.57 | 256.72 | |
| EV to operating cash flow | 520.87 | 269.5 | 402.67 | 286.77 | 357.49 | |
| EV to free cash flow | 520.87 | 269.5 | 402.67 | 286.77 | 357.49 | |
| Earnings yield | 0 | -0.01 | 0 | 0.01 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.02 | 0 | 0.01 | 0 | |
| Debt to assets | 0 | 0.02 | 0 | 0.01 | 0 | |
| Net debt to EBITDA | 130.53 | -2.16 | -443.75 | 0.26 | 0 | |
| Current ratio | 0 | 21 | 0 | 20.9 | 0 | |
| Interest coverage | 3.48 | -17.97 | -30.05 | 47.57 | 9.59 | |
| Income quality | 3.99 | -0.73 | -1.65 | 0.41 | 7.16 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.19 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.01 | 0 | 0.01 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 36.46 | 81.91 | 55.68 | 113.27 | 0 | |
| ROIC | 0 | -0.01 | -0.01 | 0.01 | 0 | |
| Return on tangible assets | 0 | -0.01 | 0 | 0.01 | 0 | |
| Graham Net | 127.92 | 143.61 | 102.06 | 147.21 | 0 | |
| Working capital | 1.28B | 1.78B | 1.02B | 1.86B | 0 | |
| Tangible asset value | 0 | 1.92B | 0 | 1.95B | 0 | |
| Net current asset value | 1.28B | 1.75B | 1.02B | 1.83B | 0 | |
| Invested capital | 0 | 0.02 | 0 | 0.01 | 0 | |
| Average receivables | 14M | 26.14M | 26.14M | 28.16M | 28.16M | |
| Average payables | 30.1M | 24.95M | 24.95M | 27.64M | 27.64M | |
| Average inventory | 227.83M | 172.39M | 172.39M | 201.87M | 201.87M | |
| Days sales outstanding | 0 | 22.16 | 0 | 16.17 | 0 | |
| Days payables outstanding | 0 | 31.36 | 0 | 26 | 0 | |
| Days of inventory on hand | 0 | 216.67 | 0 | 189.9 | 0 | |
| Receivables turnover | 0 | 4.06 | 0 | 5.57 | 0 | |
| Payables turnover | 0 | 2.87 | 0 | 3.46 | 0 | |
| Inventory turnover | 0 | 0.42 | 0 | 0.47 | 0 | |
| ROE | 0 | -0.01 | 0 | 0.01 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NURECA.NS Frequently Asked Questions
What is Nureca Limited stock symbol ?
Nureca Limited is a IN stock and trading under the symbol NURECA.NS
What is Nureca Limited stock quote today ?
Nureca Limited stock price is $276.25 today.
Is Nureca Limited stock public?
Yes, Nureca Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 32.53K
- Market Capitalization 2.9B
- Employee 102
- CEO Mr. Aryan Goyal
- Headquarters Chandigarh,IN
- IPO Date 2021-02-25
-
Website
https://www.nureca.com 
Nureca Limited, a B2C company, engages in the home healthcare and wellness products business in India. It offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeter, glucose meter, and thermometer; orthopedic products, including massagers, pain monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise, fitness tracking, and dental and personal care products. The company also provides mother and baby care products comprising baby feeding, carry cots, baby skincare, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG, fitness tracker, and smart weighing scale products. Nureca Limited offers its products under Dr Trust, Dr Physio, and Trumom brands. The company sells its products through third party e-commerce players, distributors, and retailers; and through its website, drtrust.in. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.
